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Preeclampsia is a complex disease of pregnancy whose physiopathology remains unclear and 
that poses a threat to both mothers and infants. Specific complex changes in women's 
physiology precede a diagnosis of preeclampsia. Understanding multiple aspects of such a 
complex changes at different levels of biology, can be enabled by simultaneous application of 
multiple assays. We developed prediction models for preeclampsia risk by analyzing six omics 
datasets from a longitudinal cohort of pregnant women. A machine learning-based multiomics 
model had high accuracy (area under the receiver operating characteristics curve (AUC) of 0.94, 
95% confidence intervals (CI): [0.90, 0.99]). A prediction model using only ten urine metabolites 
provided an accuracy of the whole metabolomic dataset and was validated using an 
independent cohort of 16 women (AUC=0.87, 95% CI: [0.76, 0.99]). Integration with clinical 
variables further improved prediction accuracy of the urine metabolome model (AUC=0.90, 
95% CI: [0.80, 0.99], urine metabolome, validated). We identified several biological pathways to 
be associated with preeclampsia.  The findings derived from models were integrated with 
immune system cytometry data, confirming known physiological alterations associated with 
preeclampsia and suggesting novel associations between the immune and proteomic dynamics. 
While further validation in larger populations is necessary, these encouraging results will serve 








The World Health Organization estimates that more than 800 women worldwide die from 
pregnancy-related causes every day, with the highest rates of maternal mortality and morbidity 
in low-income countries1. One of the main causes is the hypertensive disorder of pregnancy – 
preeclampsia - for which the only treatment is to deliver, often too early. Preeclampsia affects 
3–5% of pregnancies in the United States and up to 8% of all pregnancies globally1, and 
accounts for 10–15% of maternal deaths2 and 15–20% of preterm births3.  
 
The pathophysiology of preeclampsia is complex and is thought to be caused in part by 
abnormal placentation as well as a women’s predisposition through genetic and immunological 
factors4. It is believed that the abnormal placentation leads to a maternal inflammatory 
response4. Placental ischemia, oxidative stress and the presence of a maternal angiogenic 
imbalance are all characteristics of preeclampsia5,6, leading to endothelial and end-organ 
damage, and in some cases to stroke and even death.  
 
Specific biological processes involved in the development of preeclampsia have remained 
understudied. Early prediction of preeclampsia has remained a clinical challenge, owing to 
incompletely understood causes, various risk factors and likely multiple pathogenic phenotypes 
of preeclampsia7,8. The recent availability of high-throughput omics (including the genome, 
transcriptome, proteome and metabolome) assays, where each can be performed on small 
sample volumes, has enabled joint analyses of the high-dimensional multidomain or multiomics 
data measured from the same biological sample4,9,10. The integrated analysis may capture 
complex dynamics involved in the pathogenesis of preeclampsia that could ultimately lead to 
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novel therapeutic interventions. Furthermore, applying machine learning methods capable of 
extracting the most predictive features from high-dimensional multiomics data, could lead to 
more accurate predictive models and better early detection of women at risk to develop 
preeclampsia. 
 
In this unique study, we performed a multiomics analysis of the transcriptome, proteome, 
metabolome, lipidome, and microbiome from a coordinated set of biospecimen collected 
longitudinally from pregnant women; we then integrated immune system mass spectrometry 
features that were available for a subset of the patients; and we combined the multiomics data 
with the available clinical/demographics data and performed joint analysis. Our goals were to: 
1) build an integrated multiomics predictive model of preeclampsia; 2) compare prediction 
capabilities of different omics sets; 3) develop a simple and interpretable predictive model 
based on a small number of biomarkers that can be used for a diagnostic test; 4) identify a 
specific signature of preeclampsia; and 5) gain insights into pathways involved in the 
pathogenesis of preeclampsia.  
 
RESULTS 
Multiomics Characterization of Normal and Preeclamptic Pregnancy Over Gestation 
Thirty-three and sixteen women were included in the discovery and validation cohorts, 
respectively (Fig. 1A). Maternal characteristics, demographics, and gestational ages at delivery 
are shown in Table S1. In the discovery cohort, 17 women developed preeclampsia and 16 had 
a pregnancy unaffected with preeclampsia. Among the preeclampsia patients, severe vs. mild 
preeclampsia was observed in 10 and 7 women, respectively; early- vs. late-onset preeclampsia 
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was observed in 5 and 12 women, respectively (Table S2). An additional cohort of 16 women, 
out of which 12 had preeclampsia, was used to validate the metabolomics results. Blood 
samples were collected longitudinally at two or three time points during pregnancy (early, mid, 
and late – see Fig. 1). Plasma, urine, and vaginal swabs from each woman were used for 
measurements of cfRNA (plasma transcriptome), proteome (plasma), metabolome (plasma and 
urine), lipidome (plasma), and microbiome (vaginal swab). The number of measurements 
differed markedly among omics datasets, with transcriptome containing the highest number of 
measurements (Fig. S1A). In contrast, the number of principal components explaining 90% of 
variance, that quantifies the internal correlation of a dataset, exhibited smaller difference 
among datasets (Fig. S1B).  Thus, although the amount of data varied several orders of 
magnitude among the dataset, their variability and thus the amount of information content was 




Figure 1. Overview of the study. A. Two independent cohorts were analyzed using 6 different 
assays. B. Sample collection timeline for plasma in discovery and validation cohorts. Circles 
indicate pre-delivery sample collection times and inverted triangles indicate delivery dates for 
individual women (one per horizontal line). 
 
Machine Learning Modeling of Preeclampsia Over Gestation 
Multivariate models of preeclampsia were built for each dataset using the Elastic Net (EN) 
algorithm (see Methods). Predictions from separate models were then integrated in a final 
model using stacked regression. The performance of all models was evaluated using the leave-
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one-out cross-validation method). The integrated model exhibited high prediction accuracy 
(AUC=0.94, 95% confidence intervals (CI): [0.90, 0.99]) and outperformed predictions from each 
separate model in terms of the point estimate (Fig. 2). EN models generated from the proteome 
and urine metabolome exhibited high performance (AUC=0.89, 95% CI: [0.83, 0.96]; AUC = 0.87, 




Figure 2. Single- and Multi-omics machine models for preeclampsia. Performance comparison 
of machine learning models shown on x-axis in terms of the area under the receiver operator 
curve (AUC) shown on y-axis. The integrated (stacked) model utilizing stacked regression 
exhibited the highest accuracy (AUC=0.94, 95% CI [0.9, 0.94]). Both proteome and metabolome 
(urine) had high prediction performance (AUC=0.89, 95% CI [0.83, 0.96] proteome; AUC = 0.87, 


























































In order to test the applicability of these models to resource-limited settings, machine learning 
models were developed that use a small set of the most informative features from the plasma 
proteomic and urine metabolomic datasets – the two sets that had the best prediction accuracy 
– as follows. For each data set, in each cross-validation step, we used a subset of features 
selected by EN to refit a regression model. The performance of refitted models as a function of 
the number of features is shown in Fig. 3A. The best prediction model was obtained with 30 
urine metabolites. A model using only ten metabolites provided the accuracy of the whole urine 
metabolomic dataset (AUC=0.88, 95% CI: [0.81, 0.95]) (Figs. 3A and 3B). Top urine metabolites 
included adenine, isovalerylglutamic acid, uric acid ribonucleoside, N-Acetyl-O-
acetylneuraminic acid, 1,5-anhydroglucitol, dehydroepiandrosterone, sialyllactose, N-epsilon-
acetyl-L-lysine, imidazolelactic acid, and nonanoylcarnitine. The levels of predictive metabolites 
differed greatly between control and preeclamptic women (Fig. 3C) and these differences were 
usually present during each trimester. As expected, EN models varied slightly due to variability 
of the chosen training set in each leave-one out cross-validation step11 and therefore, the ten 
metabolites chosen by EN varied slightly across cross-validations. We recorded frequency of 
occurrence for every feature across all cross-validation steps (Fig. S2). Having high frequency of 
occurrence indicates that the feature is relevant for all or a majority of patients, that is, it is 
more stable11. The model using ten urine metabolites was validated in an independent cohort, 
with an AUC of 0.87 (95% CI: [0.76, 0.99]) (Fig.4).  
 
A model using the ten top-scoring plasma proteins achieved an AUC of 0.83 (95% CI: (0.73, 
0.92]) (Figs 3A and 3B.) The most predictive plasma proteins selected by EN included leptin 
(LEP), vascular endothelial growth factor A (VEGFA), L-selectin (SELL), E-selectin (SELE), 
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interleukin-24 (IL-24), interleukin-22 (IL-22), and tyrosine-protein kinase transmembrane 
receptor (ROR1) (Fig. 3D).  
 
Figure 3. Refitted model for prediction of preeclampsia in resource-limited settings: urine 
metabolomic and plasma proteomic data sets. A. Cross-validated performance of the refitted 
models as a function of the number of features (support) for urine metabolome (blue) and 
proteome (orange). The best performance is observed for a model with 30 features. A model 
using ten metabolites provided the accuracy of the whole urine metabolomic dataset 
(AUC=0.88, 95% CI: [0.81, 0.95]).  B. Performance of cross-validated prediction model using ten 
metabolites (blue) or ten proteins (orange).  For the urine metabolome, prediction from ten 












































































































































































































0.88, 95% CI [0.81, 0.95]). Prediction from ten proteins yielded performance of AUC = 0.83, 95% 
CI: [0.73, 0.92]. C. Most informative metabolites. Y-axis shows a metabolite value stratified by 
normal pregnancy (grey) and preeclamptic pregnancy (blue).  D. Most informative proteins. Y-




Figure 4. Validated model from urine metabolome using ten metabolites from the validation 
cohort. A. Area under the receiver operating curve, AUC = 0.874, 95% CI of [0.76, 0.99]. B. 
Prediction values (scores) for controls and preeclampsia (PE) groups. 
 
In order to explore multiomics interactions of analytes associated with preeclampsia, 
correlation network for controls and preeclampsia patients were generated (Fig. 5). While some 
features retained their close correlations (e.g. LEP and urine metabolite N-Acetyl-O- 
acetylneuraminic acid) in preeclampsia patients (Fig. 5B) relative to controls (Fig. 5A), some 










































clusters in the correlation network for the two groups of patients, potentially reflecting 
differential mechanisms in preeclampsia. 
 
 
Figure 5. Visualization of predictive features of transcriptome (yellow), proteome (orange), 
urine metabolome (dark blue), and plasma metabolome (light blue). Size of each node is 
proportional to the frequency at which it was chosen in prediction models during cross-
validation. High frequency of occurrence indicates that a feature is relevant for all or a majority 
of patients resulting in a more stable model.  A. Controls. B. Preeclampsia patients.  We observe 





































































Prediction of Preeclampsia in Early Pregnancy 
From a clinical perspective, early prediction of preeclampsia (i.e., within the first 16 weeks of 
gestation) is of critical importance as it would allow for early treatment of high-risk women 
(e.g., with low-dose aspirin12). It would also enable closer monitoring of high-risk pregnancies 
and allow for the enrichment of preemptive interventional studies in women at risk for 
developing preeclampsia. 13. Finally, the development of a simple and affordable diagnostic test 
would facilitate more ubiquitous testing in both high-income and low- and middle-income 
countries. For these reasons, an EN model using only biological data from samples collected 
only during first 16 weeks of pregnancy was derived. Plasma proteome and urine metabolome 
datasets generated predictive models with the highest performances (AUC=0.88, 95% CI: [0.75, 
1]; AUC=0.83, 95% CI: [0.69, 0.98], respectively, Fig. S4A) similarly to what we observed when 
using all samples collected during pregnancy. The refitted model with 10 features for the 
plasma proteome and urine metabolome provided high accuracy (AUC=0.88, 95% CI: [0.75, 1]; 
AUC=0.87, 95% CI: [0.74, 1], respectively, Fig. 6A). The most predictive metabolites and proteins 
also had high frequency of occurrence in the leave-one-out validation (Fig. S3). The heatmap of 
rank values of features selected by EN in the refitted models from all omics sets shows that 
these features distinguish women with preeclampsia from controls with no misclassification 
error (Fig. 6B). The plasma levels of the top-ranking proteins (Fig. 6C), urine metabolites (Fig. 
S4B) and genes (Fig. S4C) selected by EN, measured early in pregnancy, markedly differed 
between controls and preeclamptic women. Fig. 7 summarizes the most predictive plasma 
protein and urine metabolites both in early pregnancy and during entire pregnancy. Plasma 
proteins that were predictive in both models included LEP, SELL, CCL23, HIPK3, APCS, GPNMB, 
and IL-24, while some were mostly predictive in early pregnancy (FGF19, TIMP2), and others 
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over entire gestation (VEGFA, SELE, SPARCL1, APOB, ROR1, and IL-22) (Fig. 7A). Urine 
metabolites that were predictive over entire gestation mostly differed from urine metabolites 
predictive in early pregnancy (Fig 7B) with the exception of adenine and nonadienoylcarnitine. 
 
 
Figure 6. Prediction models in early pregnancy.  A. Performance comparison of EN models 
derived from different omics data sets using the top-ranked ten features, in terms of the AUC.  
The plasma proteomic and the urine metabolomic models performed best (AUC=0.88, 95% CI of 
[0.75, 1] for proteome; AUC=0.87, 95% CI of [0.74, 1] for  urine metabolome). B.  Heatmap of 















































controls. C. Top eight proteins. Y-axis shows the value in early pregnancy stratified by normal 
(grey) versus preeclamptic pregnancy (light-blue). 
 
Figure 7. Biomarker comparison: entire pregnancy vs. early pregnancy. X-axis and Y-axis show the 
respective frequency of each biomarker in early pregnancy and over gestation. A. Most predictive 
proteins. B. Most predictive urine metabolites. Blue circles around dots imply the same position for 
more than one protein/urine metabolite. 
 
Single Cell Characterization of the Immune System 
Preeclampsia is strongly associated with inflammation and aberrant maternal immune system 
adaptations during pregnancy14. To assess immunity -- which is complementary to pathways 
covered by proteins and metabolites – and connect differential abundances of plasma proteins 
and urine metabolites in preeclamptic pregnancies to biological changes, immune-system wide 





























































were integrated with our plasma proteome and urine metabolome prediction models, as these 
two models had the best accuracy. Immune cell dynamics between 1st and 2nd trimester blood 
samples obtained from high-dimensional mass cytometry were previously used to develop a 
prediction model of preeclampsia15. We found that seven of the immune features reported by 
Han et al. correlated highly with the prediction based on our integrated algorithm (Spearman 
correlation 𝑝 <  0.05) (Figure 8A, highlighted in orange), confirming the predictive value of 
both immune cell features as well as plasma proteins and urine metabolites. To investigate 
whether this correlation between predictive features was biologically meaningful, we focused 
on the correlations of feature behavior between the eight earlier reported predictive immune 
features (Fig. 8A) and the top twelve most informative plasma proteome features (Fig. 3E) 
across pregnancy (Fig. 8B). Leptin (LEP) and soluble L-Selectin (SELL) levels were particularly 
strongly correlated with the eight immune cell features (Fig. 8B). Interestingly, basal pSTAT5 
signaling in Th1 cells (CD4+Tbet+), the top immune feature to distinguish control from 
preeclamptic pregnancies (Han et al. 2019), correlated with LEP levels in both control and 
preeclamptic patients. Uniquely in preeclamptic cases, LEP levels were correlated with basal 
pSTAT1 signaling in intMCs  (Spearman correlation 𝑝 =  0.002) and basal STAT5 signaling in 
mDCs (Spearman correlation 𝑝 =  0.01). Moreover, SELL levels were uniquely correlated with 
immune features in preeclamptic pregnancies and not with controls, i.e. correlated with basal 
pNFkB and pSTAT1 signaling in cMCs, basal pSTAT5 signaling in Th1 cells and mDCS, and basal 
pMAPKAPK2 signaling in naive CD4 Tcells.  Preeclamptic pregnancies were not characterized by 
- in other words, had potentially lost - concerted proteome/immune behavior which was 
prominently observed in healthy pregnancies, i.e. correlations of leptin with basal pP38 
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signaling in Treg and TCRgd cells. These correlations exemplify the biological connection 
between responsiveness of immune cells and its plasma environment. 
 
Figure 8.  A. Visualization of immune features. Visualization indicates features most correlated with 
the prediction of the stacked model. Features shown in orange are the seven most predictive 
immunome features that also highly correlate with the multiomics predictive model. Size of each 
node is proportional to the -log10(p-value) of spearman correlation. B. Comparison of p-value of 
correlation for the top immune and top proteome features. Each node is a pair comprising an 







Relationship Between Clinical Data and Omics Measurements  
Clinical and demographics data contains maternal characteristics known to be associated with 
the risk of preeclampsia, e.g., preexisting hypertension, race, BMI, height, gravida. We 
combined ten variables that were available in this data set (Table S1) with the most predictive 
sets: 1) plasma proteome and 2) urine metabolome models, to better understand their mutual 
relationship. The ten clinical variables were included together with the top ten omics features – 
all combined in the single cross-validation step. Inclusion of clinical and demographics data 
improved the performance both when combined with the plasma proteome and the urine 
metabolome (urine metabolome AUC=0.96, 95% CI: [0.92, 0.99] and; proteome AUC=0.91, 95% 
CI: [0.85, 0.97], respectively) (Fig. 9A). The most predictive clinical variables included maternal 
age, BMI, height, and preexisting hypertension. We observed several significant correlations 
(Spearman correlation 𝑝 <  0.05) between clinical variables and plasma proteins/urine 
metabolites that were present only among preeclamptic women. These included: leptin with 
maternal BMI/weight, in agreement with existing literature16; CCL23 with height; SELL with 
gravida (Fig. 9B); maternal age with adenine – previously observed17 – and maternal age with 




Figure 9. Relationship between urine metabolome and proteome with clinical features over 
gestation. A. Prediction accuracy  of urine metabolome and plasma proteome. Dark blue (for 
urine metabolome) and orange (for proteome) bars show performance without clinical data 
(proteome: AUC = 0.83, 95% CI: [0.73, 0.92); urine metabolome: AUC = 0.88, 95% CI [0.81, 
0.95]). Grey bars show performance with clinical data (proteome AUC=0.91, 95% CI: [0.85, 
0.97];  urine metabolome AUC=0.96, 95% CI: [0.92, 0.99]). B. Comparison of p-value of 
correlations of the top proteome and clinical features. Value of − log10 𝑝 for preeclamptic 
patients and controls is shown on x-axis and y-axis, respectively. Each node is a pair of a 
proteome and a clinical feature. C. Comparison of p-value of correlations of the top urine 









Exploration of Preeclampsia Pathogenesis from Multiomics Measurements  
Over the Course of Pregnancy 
Changes over gestation of 1215 metabolic features among 8718 were significantly associated 
with preeclampsia outcome (FDR < 0.05 LME Model with Benjamini-Hochberg procedure). 
Pathways enrichment analysis using these urine metabolites identified the following      
pathways (p<0.05) (Fig. 10A): 1) tryptophan metabolism; 2) caffeine metabolism; 3) tyrosine 
metabolism; 4) steroid hormone biosynthesis; 5) pentose and glucuronate interconversions; 6) 
linoleic acid metabolism. The steroid hormone biosynthesis pathway plays an important role in 
pregnancy progression18. Both the steroid hormone biosynthesis pathway and the caffeine 
metabolism pathways have previously been associated to pregnancy19, and tryptophan 
metabolism with preeclampsia20. Metabolites in the steroid hormone biosynthesis pathway and 
in the caffeine metabolism pathway present in the data with high level of significance are 
respectively shown in Figs. S5C and S5D.  
 
Among 1305 proteins, 437 had changes that were significantly associated with preeclampsia 
outcome over gestation (FDR < 0.05 LME Model with Benjamini-Hochberg procedure). The top 
64 proteins at significance level  𝑝 < 5 ∙ 10−4 (LME Model) showing markedly different values 
between normal and preeclamptic women are depicted in Fig. S6. Top proteins included 
interleukin-1 receptor accessory protein (IL1RAP) and SELL – both known to play a role in the 
immune response21 (Fig. S5). Enriched pathways grouped into ten biological processes, the 
most prevalent being positive regulation of cellular process (including biological, cellular, 
protein metabolic, immune system, and apoptotic processes among others) (Fig. S7). In the 
cfRNA set, 306 features were significantly associated with preeclampsia outcome over gestation 
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(FDR < 0.05 LME Model with Benjamini-Hochberg procedure) resulting in several enriched 
pathways (Fig. S8). Top features included YOD1, BIRC2, CEP63, and LCP1. Top proteome, 




In early pregnancy, 497 out of 8718 urine metabolic features had changes significantly 
associated with preeclampsia when compared to controls (FDR<0.05, Wilcoxon signed-rank test 
with Benjamini-Hochberg procedure). Pathways enrichment analysis on these urine metabolites 
identified the following pathways (p < 0.05) (Fig. 10B): 1) tyrosine metabolism; 2) lysine 
degradation; 3) tryptophan metabolism; 4) phenylalanine metabolism; 5) steroid hormone 
biosynthesis; 6) arachidonic acid metabolism which is a central regulator of the inflammatory 
response and has a known role in the pathogenesis of preeclampsia22 ; 7) phenylalanine, 
tyrosine and tryptophan biosynthesis and; 8) aminoacyl-tRNA biosynthesis. Individual 
metabolite from these two pathways are shown in Figs. S5A and S5B. 
 
In the proteome set containing 1305 proteins, three proteins -- LEP, CCL23 and FAM3D -- were 
significantly associated with preeclampsia outcome (FDR<0.05, Wilcoxon signed-rank test with 
Benjamini-Hochberg procedure) identifying one significantly enriched pathway, negative 





Figure 10. Identified enriched pathways from urine metabolome urine over gestation and in early 
pregnancy. A. Pathways enrichment analysis over gestation using metabolites from urine that were 
significant (FDR<0.05, Wilcoxon signed-rank test with Benjamini-Hochberg procedure). Pathways 
shown above the dotted line were significant (p < 0.05). B. Pathways enrichment analysis for early 
pregnancy using metabolites from urine that were significant (FDR<0.05, Linear Mixed Effects model 
with Benjamini-Hochberg procedure). The color and the size of a circle are proportional to the 
−𝑙𝑜𝑔(𝑝) and pathway impact value, respectively, where 𝑝 denotes a p-value.   
 
Outlier analysis 
We observed that a few patients in our cohort were consistently misclassified by our prediction 
algorithm (Fig. S10). A few control patients resembled preeclamptic patients on a molecular 
level in some of the top predictive features, across omics sets. And vice versa, there were some 
preeclamptic patients whose top molecular features more closely resembled those of controls. 

































clearly hypertensive, had proteinuria in the context of gross hematuria obscuring whether 
proteinuria related to preeclampsia. Therefore, the patient may have been misdiagnosed with 
preeclampsia but rather only had gestational hypertension. This highlights that the predictive 
model can pick up discrepancies within the clinical chart. For the other patients whose clinical 
diagnosis held, this implies that their phenotypical features that were classifying these patients 
in either control or preeclampsia group, did not match their molecular phenotypes. Of interest, 
one patient in the preeclamptic group, that prediction classified as control, developed HELLP 
very late in gestation at 41+3 weeks. So, if she had delivered closer to the due date, she would 
have been considered a control.  Thus, if others in the control group have similar molecular 
phenotype this may represent a late-onset preeclampsia related to placental aging in the post-
term period.      
 
DISCUSSION 
Recent omics studies of preeclampsia typically included up to two omics datasets10,23,24. Ours is 
the first study to present the integrated analysis of six high-throughput omics datasets, 
containing more than 50,000 measurements per sample. This multiomics analysis enabled 
uniform comparison of omics sets, and revealed improved predictive ability for preeclampsia 
status relative to individual biological modalities, and indications of biological processes 
associated with the disease across multiple modalities.  
 
One of the main strengths of our study is that, in our cohort, biological samples were not only 
collected longitudinally from each woman; but also, each individual sample was simultaneously 
measured for proteome, transcriptome, metabolome, lipidome, and vaginal swab for 
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microbiome, thereby providing a unique opportunity to systematically study changes due to 
preeclampsia over gestation, and compare the capability of each of these omics sets to predict 
and characterize preeclampsia. These analyses involved more than 50,000 measurements, 
which were used in the prediction algorithm to agnostically identify the best biomarkers of 
preeclampsia.  
 
Among our six datasets, plasma proteomic and urine metabolomic datasets had the highest 
prediction accuracies, both over gestation and early in pregnancy. A prediction model using 
only ten urine metabolites provided high accuracy over gestation (AUC=0.88, cross-validated 
and AUC = 0.87 validated on an independent cohort) and early in pregnancy (AUC=0.875, cross-
validated). 
 
The EN prediction model with ten plasma proteins achieved AUC of 0.83 over gestation and of 
0.88 in early pregnancy. Vascular endothelial growth factor A (VEGF-A) was among the most 
predictive proteins. Reduced levels of VEGF-A have previously been described in preeclamptic 
pregnancies due to increased levels of placental soluble fms-like tyrosine kinase-1 (sFLT-1) 
which validate our study 25–27. Observed changes in several other proteins such as LEP, SELL, 
SELE, and ROR-1, were in agreement with existing literature21,28–30. Other biomarkers including 
IL-24, IL-22, CCL23, and HIPK3 were also identified as highly predictive. In early pregnancy, 
FGF19 and TIMP2 were the most predictive.  Univariate analysis also identified IL1RAP and IL6 - 
features known to play a role in immune response. Some of the other known biomarkers of 
preeclampsia – sFLT-1, PAPP-A, PIGF and ENG – were not significantly different between the 
controls and preeclamptic women neither over gestation, nor early in pregnancy (Fig. S11) and 
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were, consequentially, not identified by our prediction model. This is possibly due to a small 
size of our cohort.  We did not have PP13 (Galectin13) measurements, another known 
biomarker of preeclampsia. 
 
Preeclampsia is accompanied by a dysregulated maternal immune adaptation to pregnancy, 
which is already detectable in early pregnancy14,15. This aberrant signature was previously 
identified in women who developed preeclampsia later on15. Here we report that the intricate 
functional capacities of immune cells are co-evolving with their environment throughout the 
course of pregnancy, showing that top informative immune feature levels are highly correlated 
with top informative plasma protein levels. This interconnectedness supports both prediction 
approaches, confirming their individual usefulness, while complementing each other’s validity. 
Specifically, the results highlight known pathology of preeclampsia and suggest novel 
associations between immunological and proteomic dynamics. In preeclamptic pregnancies, 
immune responses were uniquely correlated with levels of leptin and soluble L-Selectin. 
 
Leptin, known to be elevated in the plasma of pre-eclamptic women31, is an immune regulatory 
hormone produced by adipose tissue and by the placenta31,32. Leptin activates the JAK/STAT 
and MAPK pathway, directly through binding to the leptin receptor expressed on leukocytes 
and thereby modulates both innate and adaptive immune responses33,34, including skewing of 
CD4 T cells towards Th1 polarization35 and inhibiting Treg proliferation34. Accordingly, we 
observed that leptin levels in preeclamptic and control pregnancies correlated with STAT and 
MAPK pathway signaling both in innate and adaptive immune cells, suggesting that 
dysregulated leptin levels in preeclamptic pregnancies might contribute to the aberrant 
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immune signature, while, reciprocally, inflammation itself might enhance plasma leptin 
levels32,33. Moreover, while in healthy pregnancies leptin levels correlated with pP38 signaling 
in Treg and TCRgd, this correlation was lost in preeclamptic pregnancies, suggesting that 
regulation of immune tolerance might be disrupted in preeclamptic pregnancies.  
 
Further, we reported decreased L-Selectin levels in preeclamptic pregnancies that correlated 
with basal pSTAT, pNFkB and pMAPKAP2 signaling in innate (mDC and cMC) and adaptive 
immune cells (Th1 and naive CD4 T cells). L-Selectin is shed from leukocytes during activation 
and migration, and soluble L-Selectin can be used as a surrogate marker for inflammation36. 
Notably, a drop in soluble L-Selectin levels is observed during sepsis37. Previous studies 
reported conflicting results for circulating sL-Selectin levels in preeclampsia38–40 , including low 
sL-Selectin levels at 20 weeks of gestation, prior to onset of preeclampsia39. Pre-eclampsia-
associated enhanced ectodomain shedding of cell adhesion molecules could be directly linked 
to changes in signaling responses in circulating immune cells by shedding-mediated activation 
of intracellular pathways36. Alternatively, the correlation could reflect independent 
inflammatory mechanisms as decreased levels of circulating L-Selectin have been proposed to 
be due to its adsorption to luminal vascular ligands, which are upregulated by an activated 
endothelium, a feature of pre-eclampsia6,39,41. 
 
The model with urine metabolites was the most performant to predict PE condition.  
Enrichment analysis identified discriminant biological pathways associated with PE when 
considering early and all time points. Steroid hormone biosynthesis pathway was significant 
(𝑝 < 0.05) in both models while arachidonic acid metabolism was significant in early 
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pregnancy. Arachidonic acid (AA) is a precursor to a myriad of bioactive lipids including 
prostaglandins (PG), prostacyclin, thromboxane, HPETE, leukotrienes, lipoxins, hypoxins, 
anandamide, and epoxyeicosatrienoic acids, that play key roles in inflammatory, vascular and 
coagulation processes42. As early as the 1960’s the role of the eicosanoids in preeclampsia 
pathogenesis was proposed and by the 1970’s evidence supported that an increase in 
thromboxane (TXA2; produced by platelets) over prostacyclin (PGI2; produced by endothelium) 
associated with preeclampsia43. This is one of the biological underpinnings for the use of low-
dose aspirin for the prevention of preeclampsia. Mills et al.44 reported longitudinal 
measurements of the urinary metabolites of thromboxane and prostacyclin throughout 
gestation. Although they did not find a significant increase in the urinary concentrations of 
TXA2, they did find a significant decrease in PGI2 as early as 13–16 weeks of gestation and a 
significant elevation in the ratio of thromboxane to prostacyclin as early as 17–20 weeks of 
gestation in women destined to develop preeclampsia. While this PG imbalance is noted both 
prior to and at the time of clinical presentation (after 20 weeks), the fact that AA metabolism 
was only observed in early pregnancy may explain why clinical studies note that low-dose 
aspirin initiation prior to 16 weeks is needed for significant prevention of preeclampsia45.  
 
Tryptophan pathway was identified as highly associated with preeclampsia over gestation (Fig 
10A). Indoleamine- 2,3- dioxygenase (IDO) is the first and rate limiting enzyme in this pathway 
producing kynurenine which then is converted into a number of bioactive metabolites. IDO is 
an intracellular enzyme produced by many cell types and while not secreted, impacts 
neighboring cells by tryptophan depletion and production of bioactive metabolites. The role of 
IDO in both normal and abnormal pregnancies, including preeclampsia, has been recently 
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reviewed46. IDO expression increases with pregnancy and tryptophan depletion in the placenta 
inhibits T- cell- mediated rejection of semiallogeneic fetal tissues47. Kynurenine is an 
endogenous ligand that activates the aryl hydrocarbon receptor (AhR)48. This activation skews 
the differentiation of T cells to immunosuppressive T regulatory cells rather than 
proinflammatory Th17 cells after exposure to TGF- β49,50. Notably, kynurenic acid and 
xanthurenic acid, two metabolites of kynurenine, can also activate AhR signaling and may 
participate in immune regulation51,52. Therefore, deficiency of IDO impacts Treg development. 
Notably, IDO KO mice, when pregnant, develop a preeclampsia-like phenotype53. The metabolic 
signal related to tryptophan metabolism in the model over gestation  may be related to the 
immune signature of preeclampsia, highlighting the importance of the immune alteration 
occurring in the later stages of preeclampsia. Caffeine metabolism was also identified as highly 
associated with preeclampsia over gestation. This pathway has previously been associated to 
pregnancy progression19. 
 
Models to predict preeclampsia early in pregnancy were previously based on maternal 
characteristics (demographics and medical history), followed by addition of uterine artery 
Doppler measurements and specific biomarkers54–59. Levels of angiogenic and/or anti-
angiogenic proteins (PlGF, sFlt-1, and endoglin), or their ratios, have been established as 
biomarkers with high prediction accuracy later in pregnancy25,26,60. More recently, analysis of 
omics datasets have been successfully applied to identify various biomarkers related to 
preeclampsia10,23,61. Most of these studies were based on measurements from one or at most 
two omics datasets, and often from samples taken only at one time point during pregnancy. 
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Here we show that clinical and demographics characteristics (i.e., weight, height, race) were 
complementary to omics measurements and improved prediction models 
 
Our study is limited by a small sample size and consideration of a cohort from a single hospital. 
Inherently to machine learning approach, developing a prediction model depends on the 
underlying sample distribution of the data which is used. Distribution shift, caused by 
differences among various cohorts, can impact the performance of a machine learning 
algorithm62. In this study, the mass cytometry data was not included in the multiomics 
prediction model because this data was not available for 14 out of 33 patients. However, 
integrative analysis on the restricted set of common samples revealed important connections 
between our model and key immune features. 
 
While encouraging, our results need to be validated on a larger, more diverse set of patients. If 
the results prove generalizable, our findings demonstrating high predictive power from a small 
number of urine metabolites and proteins could lead to a simple prediction test based on a 
small number of urine metabolites suitable for use both in developed and developing parts of 




We performed a longitudinal, prospective study of a cohort of pregnant women receiving 
routine ante- and post-partum care at the Lucile Packard Children’s Hospital at Stanford 
University, California, as previously described15,63. Women were eligible for the study if they 
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were at least 18 years of age and were in their first trimester of pregnancy. The study was 
approved by the Institutional Review Board of Stanford University (#21956), and all participants 
signed an informed consent. 
 
Peripheral blood samples (for mass cytometry analysis), plasma samples (for proteomic, cell-
free transcriptomic (cfRNA), metabolomic, and lipidomic analyses), urine samples (for 
metabolomics analysis), and vaginal swabs (for microbiome analysis) were collected from each 
woman at two or three time points during pregnancy. Sample collection and their analyses 
were previously described9 and are presented in the Supplemental Materials. The validation 
cohort included 16 women from the same hospital, for which longitudinal samples with only 
metabolomic analyses were available. Metabolomic analyses were performed following the 
same methodology as for the discovery cohort.  
 
Definition of Preeclampsia 
Preeclampsia was defined using the American College of Obstetrics and Gynecology 
classification3 as follows: hypertension that develops after 20 weeks of gestation (systolic or 
diastolic blood pressure 140 mm Hg and/or 90 mm Hg, respectively, measured on at least two 
occasions, 4 hours to 1 week apart) and proteinuria (300 mg in a 24-hour urine collection, a 
protein/creatinine ratio of at least 0.3 (each measured as mg/dL) or if these were not readily 
available a random urine specimens containing 1+ protein by dipstick). In the absence of 
proteinuria preeclampsia was diagnosed if the presence of thrombocytopenia (platelet count 
less than 100,000/microliter), impaired liver function (elevated blood levels of liver 
transaminases to twice the normal concentration), the new development of renal insufficiency 
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(elevated serum creatinine greater than 1.1 mg/dL), pulmonary edema, or new-onset cerebral 
or visual disturbances. Early-onset  and late-onset preeclampsia were distinguished based on 
whether diagnosis was before or after 34 weeks of gestation. 
 
Machine learning analyses  
A two-level cross-validation approach was used to build predictive models to estimate the risk 
of preeclampsia.  At the first level, prediction models were developed for each omics set using 
an elastic net (EN) model64. Given 𝑁 × 𝑝 matrix of predictors (measurements) 𝑋 = (𝑥1, … 𝑥𝑝)  
and a vector of responses 𝑦 = (𝑦1, … , 𝑦𝑁) , regression coefficients 𝛽 = (𝛽1, … , 𝛽𝑝) and an 
intercept term 𝛽0 in the EN model are obtained  by maximizing the likelihood, or equivalently 







𝐿(𝛽0, 𝛽; 𝑦, 𝑋) + 𝜆((1 − 𝛼)‖𝛽‖2 + 𝛼‖𝛽‖)]  
Logistic regression was used, for which the negative log-likelihood evaluates to: 




𝑇𝛽) − 𝑙𝑜𝑔 (1 + 𝑒𝛽0+𝑥𝑖
𝑇𝛽)  
For the high-dimensional setting (𝑝 ≫ 𝑁) considered here, EN, which performs both shrinkage 
and automatic selection of predictors, can provide both high accuracy and facilitate 
interpretability.  
 
At the second level, predictions of EN models were integrated using stacked regression65–67. 
Specifically, in order to use EN models in the two-level approach, for each modality 𝑘, 𝑘 =
1, … 𝐾 and data 𝑋𝑘 = (𝑥1
𝑘 , … 𝑥𝑝𝑘
𝑘 )  a leave-one-out EN model, denoted 𝑐−𝑖
𝑘 (𝑥𝑖) was repeatedly 
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fitted and evaluated at patient 𝑖. At the second level, stacked regression with nonnegative 
coefficients11 was used, so that the regression coefficients of the final model (𝛾1, … , γK)  were 











  𝑠. 𝑡.  𝛾𝑖 ≥ 0.   
Note that the leave-one-out approach used in stacked regression has a purpose to form an 
unbiased linear combination of EN models66. In contrast to the original stacking approach in 
which different prediction models fit on the same data are stacked, here, we use the same 
model (EN) but fit to different omics to obtain different estimators which are then stacked. A 
stacked regression model can be regarded as a special case of a two-layer neural network; its 
special construction provides for an easier interpretation. 
 
One of our main goals was to identify a small subset of specific biomarkers that can predict 
preeclampsia with high accuracy and could thereby be used as a simple diagnostic test.  For 
these reasons, performance of the refitted EN model for each omics set  was evaluated by 
treating the EN model as a model-selection procedure and performing a refitting step on the 
selected support, in the same cross-validation step68. It is known that 𝐿1-penalization used in 
EN performs excessive shrinkage of the large coefficients of the prediction model69. Refitting 
can resolve this problem and obtain a model with a smaller number of features. Finally, to 
investigate a possible gain from integration of available clinical and demographics 
characteristics, a prediction model that takes omics (from a specific multiomics set), and clinical 
and demographics variables as an input to an EN model was fit and evaluated. 
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Performance was estimated using a leave-one-out cross-validation procedure, such that in each 
cross-validation step all measurements of one patient are left out from training set and are 
used for testing. In addition, urine metabolome prediction models, with and without 
clinical/demographics variables were validated on a separate validation cohort. The prediction 
accuracy of the model in terms of the area under receiver operating characteristics curve was 
evaluated. For the network visualization, a k-nearest neighbor graph (with 𝑘 = 2), was 
constructed between features. The network layout was computed with the LargeVis 
algorithm70. The analysis was performed using R software (version 3.6.1). 
 
Pathway Enrichment Analysis 
Univariate analysis was performed to identify features with significant associations between 
each feature and the pregnancy outcome, both in early pregnancy (Wilcoxon signed-rank test) 
and over gestation (Linear Mixed-effects Model). The Benjamini-Hochberg procedure was used 
to control the false discovery rate (FDR)71. Metabolome pathway enrichment analysis on 
identified metabolites was performed using MetaboAnalyst72. The hypergeometric test was 
used for overrepresentation analysis in MetaboAnalyst. Proteome pathway enrichment analysis 
was performed using GeneOntology73,74. Circular Gene Ontology (CirGO) software for visualizing 
two-level hierarchically structured gene ontology terms75, was used to visualize proteome and 
transcriptome pathway enrichment.  
 
ACKNOWLEDGEMENTS: 
This study was supported by the March of Dimes Prematurity Research Center at Stanford 
University School of Medicine, Stanford Maternal & Child Health Research Institute, the 
 34 
Christopher Hess Research Fund, the National Institutes of Health, grants 1R01HL139844 and 
R35GM138353, Burroughs Wellcome Fund,  and grants from the Bill & Melinda Gates 
Foundation OPP1112382 and OPP1113682. M.P.S. was supported by National Institutes of 
Health, grant 5RM1HG00773507. D.A.R was supported by the Thomas C. and Joan M. Merigan 
Endowment at Stanford University and the Chan Zuckerburg Biohub Microbiome Initiative. 
 
AUTHOR CONTRIBUTIONS: 
I.M. and N.A. designed machine learning experiments and performed interpretation of results; 
I.M performed computational analysis and wrote the paper;  N.A. provided guidance and 
feedback and contributed to writing the paper; K.C. performed MS metabolomic analysis and 
contributed to metabolomic pathway analysis and writing of the paper;  M.M.  performed cell-
free RNA transcriptome analysis; I.S., D.F., and X.H performed immunome analysis and 
contributed to writing the paper; A.T. performed part of the computational analysis; N.S. 
assisted with the computational analysis; R.J.W. supervised the study data collection and edited 
the manuscript; G.M.T and M.E performed MS metabolomic analysis; N.S., A.C., R.F., H.N., M.B., 
M.X., C.E., D. D. F., M.S.G., A.Cu. helped with editing the manuscript; E.C. performed 
microbiome analysis; X.B.L and K.G.S., G.L.D., D.A.R., S.R.Q., M.A. provided critical feedback on 
the study and edited the manuscript; D.A.R. was involved with the microbiome analysis;  M.P.S. 
was involved in the MS metabolome analysis; V.D.W. wrote a part of the paper and contributed 
to interpretation of results; G.M.S. provided the study data, provided guidance and feedback, 
contributed to interpretation of results and edited the manuscript; B.G. designed the 
immunome part of the analysis, performed interpretation of the results and edited the 
 35 
manuscript; D.K.S. provided the study data, provided guidance and supervised the research. All 
authors discussed results, and contributed to the final manuscript. 
 




1. WHO, UNICEF, UNFPA, World Bank Group and the United Nations Population Division. 
Maternal mortality: Levels and trends2000 to 2017. (2019). 
2. Duley, L. The global impact of pre-eclampsia and eclampsia. Semin Perinatol 33, 130–137 
(2009). 
3. Jeyabalan, A. Epidemiology of preeclampsia: impact of obesity. Nutr. Rev. 71 Suppl 1, S18-
25 (2013). 
4. Than, N. G. et al. Integrated systems biology approach identifies novel maternal and 
placental pathways of preeclampsia. Front. Immunol. 9, 1661 (2018). 
5. Phipps, E. A., Thadhani, R., Benzing, T. & Karumanchi, S. A. Pre-eclampsia: pathogenesis, 
novel diagnostics and therapies. Nat. Rev. Nephrol. 15, 275–289 (2019). 
6. Chaiworapongsa, T., Chaemsaithong, P., Yeo, L. & Romero, R. Pre-eclampsia part 1: 
current understanding of its pathophysiology. Nat. Rev. Nephrol. 10, 466–480 (2014). 
7. Duckitt, K. & Harrington, D. Risk factors for pre-eclampsia at antenatal booking: systematic 
review of controlled studies. BMJ 330, 565 (2005). 
8. Tranquilli, A. L., Brown, M. A., Zeeman, G. G., Dekker, G. & Sibai, B. M. The definition of 
severe and early-onset preeclampsia. Statements from the International Society for the Study 
of Hypertension in Pregnancy (ISSHP). Pregnancy hypertension 3, 44–47 (2013). 
 36 
9. Ghaemi, M. S. et al. Multiomics modeling of the immunome, transcriptome, microbiome, 
proteome and metabolome adaptations during human pregnancy. Bioinformatics 35, 95–103 
(2019). 
10. Benny, P. A., Alakwaa, F. M., Schlueter, R. J., Lassiter, C. B. & Garmire, L. X. A review of 
omics approaches to study preeclampsia. Placenta 92, 17–27 (2020). 
11. Meinshausen, N. & Bühlmann, P. Stability selection. J Royal Statistical Soc B 72, 417–473 
(2010). 
12. Roberge, S. et al. The role of aspirin dose on the prevention of preeclampsia and fetal 
growth restriction: systematic review and meta-analysis. Am. J. Obstet. Gynecol. 216, 110–
120.e6 (2017). 
13. American College of Obstetricians and Gynecologists; Task Force on Hypertension in 
Pregnancy. Hypertension in pregnancy. Report of the American College of Obstetricians 
and Gynecologists’ Task Force on Hypertension in Pregnancy. Obstet Gynecol. (2013). 
14. Redman, C. W. G. & Sargent, I. L. Immunology of pre-eclampsia. Am J Reprod Immunol 
63, 534–543 (2010). 
15. Han, X. et al. Differential dynamics of the maternal immune system in healthy pregnancy 
and preeclampsia. Front. Immunol. 10, 1305 (2019). 
16. Samolis, S. et al. Relation between first trimester maternal serum leptin levels and body 
mass index in normotensive and pre-eclamptic pregnancies--role of leptin as a marker of 
pre-eclampsia: a prospective case-control study. Gynecol Endocrinol 26, 338–343 (2010). 
17. Hashimoto, M. et al. The effects of age on the release of adenine nucleosides and 
nucleotides from rat caudal artery. J. Physiol. (Lond.) 489 ( Pt 3), 841–848 (1995). 
18. Chatuphonprasert, W., Jarukamjorn, K. & Ellinger, I. Physiology and pathophysiology of 
steroid biosynthesis, transport and metabolism in the human placenta. Front. Pharmacol. 9, 
1027 (2018). 
 37 
19. Liang, L. et al. Metabolic dynamics and prediction of gestational age and time to delivery in 
pregnant women. Cell 181, 1680–1692.e15 (2020). 
20. Nilsen, R. M. et al. Maternal tryptophan and kynurenine pathway metabolites and risk of 
preeclampsia. Obstet. Gynecol. 119, 1243–1250 (2012). 
21. Luppi, P. et al. Preeclampsia activates circulating immune cells with engagement of the NF-
kappaB pathway. Am J Reprod Immunol 56, 135–144 (2006). 
22. Massobrio, M. et al. Arachidonic Acid Derivatives in the Pathophysiology of Pregnancy-
Induced Hypertension. Clinical and Experimental Hypertension. Part B: Hypertension in 
Pregnancy 7, 43–55 (1988). 
23. Tarca, A. L. et al. The prediction of early preeclampsia: Results from a longitudinal 
proteomics study. PLoS One 14, e0217273 (2019). 
24. Austdal, M. et al. First trimester urine and serum metabolomics for prediction of 
preeclampsia and gestational hypertension: A prospective screening study. Int. J. Mol. Sci. 
16, 21520–21538 (2015). 
25. Maynard, S. E. & Karumanchi, S. A. Angiogenic factors and preeclampsia. Semin Nephrol 
31, 33–46 (2011). 
26. Maynard, S. E. et al. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may 
contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J. Clin. 
Invest. 111, 649–658 (2003). 
27. Rath, G. & Tripathi, R. Angiogenic balance and diagnosis of pre-eclampsia: selecting the 
right VEGF receptor. J Hum Hypertens 26, 207–210 (2012). 
28. Poston, L. Leptin and preeclampsia. Semin Reprod Med 20, 131–138 (2002). 
29. Chen, J. et al. Downregulation of receptor tyrosine kinase-like orphan receptor 1 in 
preeclampsia placenta inhibits human trophoblast cell proliferation, migration, and invasion 
by PI3K/AKT/mTOR pathway accommodation. Placenta 82, 17–24 (2019). 
 38 
30. Hao, S. et al. Changes in pregnancy-related serum biomarkers early in gestation are 
associated with later development of preeclampsia. PLoS One 15, e0230000 (2020). 
31. Taylor, B. D. et al. Serum leptin measured in early pregnancy is higher in women with 
preeclampsia compared with normotensive pregnant women. Hypertension 65, 594–599 
(2015). 
32. Pérez-Pérez, A. et al. Leptin action in normal and pathological pregnancies. J. Cell Mol. 
Med. 22, 716–727 (2018). 
33. Naylor, C. & Petri, W. A. Leptin regulation of immune responses. Trends Mol. Med. 22, 88–
98 (2016). 
34. Abella, V. et al. Leptin in the interplay of inflammation, metabolism and immune system 
disorders. Nat. Rev. Rheumatol. 13, 100–109 (2017). 
35. Martín-Romero, C., Santos-Alvarez, J., Goberna, R. & Sánchez-Margalet, V. Human leptin 
enhances activation and proliferation of human circulating T lymphocytes. Cell Immunol. 
199, 15–24 (2000). 
36. Ivetic, A., Hoskins Green, H. L. & Hart, S. J. L-selectin: A Major Regulator of Leukocyte 
Adhesion, Migration and Signaling. Front. Immunol. 10, 1068 (2019). 
37. Seidelin, J. B., Nielsen, O. H. & Strøm, J. Soluble L-selectin levels predict survival in 
sepsis. Intensive Care Med. 28, 1613–1618 (2002). 
38. Docheva, N. et al. The profiles of soluble adhesion molecules in the “great obstetrical 
syndromes”. J. Matern. Fetal Neonatal Med. 32, 2113–2136 (2019). 
39. Chavarría, M. E., Lara-González, L., García-Paleta, Y., Vital-Reyes, V. S. & Reyes, A. 
Adhesion molecules changes at 20 gestation weeks in pregnancies complicated by 
preeclampsia. Eur. J. Obstet. Gynecol. Reprod. Biol. 137, 157–164 (2008). 
40. Sabatier, F. et al. Neutrophil activation in preeclampsia and isolated intrauterine growth 
restriction. Am. J. Obstet. Gynecol. 183, 1558–1563 (2000). 
 39 
41. Rainer, T. H. L-selectin in health and disease. Resuscitation 52, 127–141 (2002). 
42. Sonnweber, T., Pizzini, A., Nairz, M., Weiss, G. & Tancevski, I. Arachidonic acid 
metabolites in cardiovascular and metabolic diseases. Int. J. Mol. Sci. 19, (2018). 
43. Walsh, S. W. Eicosanoids in preeclampsia. Prostaglandins Leukot Essent Fatty Acids 70, 
223–232 (2004). 
44. Mills, J. L. et al. Prostacyclin and thromboxane changes predating clinical onset of 
preeclampsia: a multicenter prospective study. JAMA 282, 356–362 (1999). 
45. Cui, Y., Zhu, B. & Zheng, F. Low-dose aspirin at ≤16 weeks of gestation for preventing 
preeclampsia and its maternal and neonatal adverse outcomes: A systematic review and 
meta-analysis. Exp Ther Med 15, 4361–4369 (2018). 
46. Chang, R.-Q., Li, D.-J. & Li, M.-Q. The role of indoleamine-2,3-dioxygenase in normal and 
pathological pregnancies. Am J Reprod Immunol 79, e12786 (2018). 
47. Munn, D. H. et al. Prevention of allogeneic fetal rejection by tryptophan catabolism. Science 
281, 1191–1193 (1998). 
48. DiNatale, B. C. et al. Kynurenic acid is a potent endogenous aryl hydrocarbon receptor 
ligand that synergistically induces interleukin-6 in the presence of inflammatory signaling. 
Toxicol. Sci. 115, 89–97 (2010). 
49. Nguyen, N. T. et al. Aryl hydrocarbon receptor negatively regulates dendritic cell 
immunogenicity via a kynurenine-dependent mechanism. Proc. Natl. Acad. Sci. USA 107, 
19961–19966 (2010). 
50. Mezrich, J. D. et al. An interaction between kynurenine and the aryl hydrocarbon receptor 
can generate regulatory T cells. J. Immunol. 185, 3190–3198 (2010). 
51. Jaronen, M. & Quintana, F. J. Immunological relevance of the coevolution of IDO1 and 
AHR. Front. Immunol. 5, 521 (2014). 
52. Fazio, F. et al. Cinnabarinic acid and xanthurenic acid: Two kynurenine metabolites that 
 40 
interact with metabotropic glutamate receptors. Neuropharmacology 112, 365–372 (2017). 
53. Santillan, M. K. et al. Pregnant mice lacking indoleamine 2,3-dioxygenase exhibit 
preeclampsia phenotypes. Physiol. Rep. 3, (2015). 
54. Wright, D., Syngelaki, A., Akolekar, R., Poon, L. C. & Nicolaides, K. H. Competing risks 
model in screening for preeclampsia by maternal characteristics and medical history. Am. J. 
Obstet. Gynecol. 213, 62.e1-62.e10 (2015). 
55. Odibo, A. O. et al. First-trimester placental protein 13, PAPP-A, uterine artery Doppler and 
maternal characteristics in the prediction of pre-eclampsia. Placenta 32, 598–602 (2011). 
56. Yu, C. K. H. et al. An integrated model for the prediction of preeclampsia using maternal 
factors and uterine artery Doppler velocimetry in unselected low-risk women. Am. J. Obstet. 
Gynecol. 193, 429–436 (2005). 
57. Audibert, F. et al. Screening for preeclampsia using first-trimester serum markers and 
uterine artery Doppler in nulliparous women. Am. J. Obstet. Gynecol. 203, 383.e1-8 (2010). 
58. Wright, D., Wright, A. & Nicolaides, K. H. The competing risk approach for prediction of 
preeclampsia. Am. J. Obstet. Gynecol. (2019). doi:10.1016/j.ajog.2019.11.1247 
59. North, R. A. et al. Clinical risk prediction for pre-eclampsia in nulliparous women: 
development of model in international prospective cohort. BMJ 342, d1875 (2011). 
60. Parra-Cordero, M. et al. Prediction of early and late pre-eclampsia from maternal 
characteristics, uterine artery Doppler and markers of vasculogenesis during first trimester 
of pregnancy. Ultrasound Obstet. Gynecol. 41, 538–544 (2013). 
61. Kelly, R. S. et al. Integration of metabolomic and transcriptomic networks in pregnant 
women reveals biological pathways and predictive signatures associated with preeclampsia. 
Metabolomics 13, (2017). 
62. Recht, B., Roelofs, R., Schmidt, L. & Shankar, V. Do ImageNet Classifiers Generalize to 
ImageNet? arXiv (2019). 
 41 
63. Aghaeepour, N. et al. An immune clock of human pregnancy. Sci. Immunol. 2, (2017). 
64. Zou, H. & Hastie, T. Regularization and variable selection via the elastic net. J Royal 
Statistical Soc B 67, 301–320 (2005). 
65. Breiman, L. Stacked regressions. Mach Learn 24, 49–64 (1996). 
66. Wolpert, D. H. Stacked generalization. Neural Netw. 5, 241–259 (1992). 
67. Stone, M. Cross-Validatory Choice and Assessment of Statistical Predictions. Journal of the 
Royal Statistical Society: Series B (Methodological) 36, 111–133 (1974). 
68. Chzhen, E., Hebiri, M. & Salmon, J. On Lasso refitting strategies. Bernoulli 25, 3175–3200 
(2019). 
69. Hastie, T., Tibshirani, R. & Wainwright, M. in Statistical Learning with Sparsity: The Lasso 
and Generalizations 155–182 (Chapman and Hall/CRC, 2015). doi:10.1201/b18401-8 
70. Tang, J., Liu, J., Zhang, M. & Mei, Q. Visualizing Large-scale and High-dimensional Data. 
in Proceedings of the 25th International Conference on World Wide Web  - WWW ’16 287–
297 (ACM Press, 2016). doi:10.1145/2872427.2883041 
71. Benjamini, Y. & Hochberg, Y. Controlling the false discovery rate: A practical and 
powerful approach to multiple testing. Journal of the Royal Statistical Society: Series B 
(Methodological) 57, 289–300 (1995). 
72. Pang, Z., Chong, J., Li, S. & Xia, J. Metaboanalystr 3.0: toward an optimized workflow for 
global metabolomics. Metabolites 10, (2020). 
73. Ashburner, M. et al. Gene Ontology: tool for the unification of biology. Nat. Genet. 25, 25–
29 (2000). 
74. The Gene Ontology Consortium. The Gene Ontology Resource: 20 years and still GOing 
strong. Nucleic Acids Res. 47, D330–D338 (2019). 
75. Kuznetsova, I., Lugmayr, A., Siira, S. J., Rackham, O. & Filipovska, A. CirGO: an 
alternative circular way of visualising gene ontology terms. BMC Bioinformatics 20, 84 
 42 
(2019). 
 
 
